Latest Commercial Expansion News

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

Sprintex secures a key deposit from Mest Water to develop new compressors for mobile manure processing systems, leveraging a Dutch government subsidy aimed at thousands of small farms.

xReality Group has raised $2 million through a discounted share placement to fuel the international expansion of its Operator XR virtual reality training platform, targeting law enforcement and military sectors.

Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Firebrick Pharma has unexpectedly withdrawn its planned share placement, raising questions about its capital strategy amid ongoing product launches.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

Cardiex Limited has raised $2.4 million through an institutional placement and launched a fully underwritten entitlement offer to raise up to $4.1 million, aiming to scale its CONNEQT Pulse device.

Aurora Labs has signed a Memorandum of Understanding with Mayman Aerospace to jointly develop 3D-printed micro gas turbines for advanced VTOL aircraft, marking its strategic entry into the U.S. aerospace sector.

Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.

MTM Critical Metals has locked in a pre-permitted industrial site in Texas, positioning itself to commission its innovative metal recovery plant by year-end 2025 and accelerate U.S. commercial expansion.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.